AbbVie

Yahoo Finance • 20 hours ago

VYM Climbs 26% In a Year While Its Core Dividend Payers Extend Their Streaks

Quick Read The fund’s income stream relies heavily on five mature cash generators: Johnson & Johnson, Procter & Gamble, Coca-Cola, Exxon Mobil, and AbbVie. VYM’s distribution is durable for retirees, with four anchor holdings having fortr... Full story

Yahoo Finance • 22 hours ago

CooperVision Names Muru Annamalai as President, Asia-Pacific

Experienced Global Healthcare Leader to Guide Growth Across the Region SINGAPORE, May 29, 2026 /PRNewswire/ -- CooperVision has named Muru Annamalai as President, Asia-Pacific, effective June 1. He brings more than two decades of global l... Full story

Yahoo Finance • 22 hours ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

Addition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trial Fixed-duration VENCLYXTO-based combination re... Full story

Yahoo Finance • 22 hours ago

Discover May 2026's Stocks That Could Be Trading Below Estimated Value

The United States market has shown robust performance, rising 1.8% over the last week and climbing 28% in the past year, with earnings projected to grow by 17% annually. In this thriving environment, identifying stocks that are trading bel... Full story

Yahoo Finance • 2 days ago

FDA Greenlights AbbVie's DECNUPAZ For BPDCN, A Rare Blood Cancer

(RTTNews) - AbbVie (ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZ for the treatment of adult patients with Blastic plasmacytoid dendritic cell neoplasm or BPDCN, an ultra-rare hematologic malignancy... Full story

Yahoo Finance • 2 days ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting - DECNUPAZ marks AbbVie's first ADC approved for blood cancer NORT... Full story

Yahoo Finance • 3 days ago

PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem

The VanEck Pharmaceutical ETF(NASDAQ:PPH) provides targeted exposure to drug manufacturers, while the iShares Global Healthcare ETF(NYSEMKT:IXJ) offers a broader reach across the international medical industry including biotechnology and e... Full story

Yahoo Finance • 3 days ago

Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline Progress

AbbVie Inc. (NYSE:ABBV) ranks among the best retirement stocks to buy now. Piper Sandler increased its price target for AbbVie Inc. (NYSE:ABBV) to $298 from $294 on May 14, retaining an Overweight rating on the company’s shares. The firm m... Full story

Yahoo Finance • 4 days ago

SCHD’s Dividend Quality Filter Now Concentrates 42 Percent of Your Money in Just Ten Stocks

Quick Read Schwab U.S. Dividend Equity ETF (SCHD) holds 105 stocks but concentrates 42% of assets in the top ten positions, including Texas Instruments (TXN), UnitedHealth (UNH), and Qualcomm (QCOM), which all meet quality screens but cre... Full story

Yahoo Finance • 4 days ago

Zifo, Pistoia Alliance, and Pharma Majors Launch Global IVP Assay Repository

Repository standardizes how biological assays are captured, shared, and reused Zifo worked collaboratively with regulatory authorities and Pistoia Alliance members Steering committee included representatives from AbbVie, Novartis, Merck an... Full story

Yahoo Finance • 5 days ago

Three Stocks That May Be Trading Below Their Estimated Value In May 2026

Over the last 7 days, the United States market has risen by 1.1%, contributing to an impressive 29% climb over the past year, with earnings forecasted to grow by 17% annually. In such a robust environment, identifying stocks that may be tr... Full story

Yahoo Finance • 5 days ago

Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight

New York, USA, May 25, 2026 (GLOBE NEWSWIRE) -- Emerging Hope in Multiple Myeloma Market: 7 Late-Stage Therapies Nearing the Finish Line | DelveInsight The multiple myeloma market is evolving toward immunotherapy-dominated, multi-line t... Full story

Yahoo Finance • 5 days ago

Two Paths to Growth: Johnson & Johnson vs AbbVie

Quick Read Johnson & Johnson (JNJ) reported Q1 2026 revenue of $24.06 billion, beating expectations with 9.9% YoY growth driven by TREMFYA surging 68.3% and DARZALEX climbing 22.5% to $3.96 billion, while raising FY26 guidance to a midpoi... Full story

Yahoo Finance • 6 days ago

3 Monster Dividend Stocks to Hold for the Next 10 Years

Key Points AbbVie is a Dividend King that has demonstrated its ability to adapt effectively to daunting challenges. Enterprise Products Partners is a top pipeline stock with an especially attractive distribution. NextEra Energy is a util... Full story

Yahoo Finance • 7 days ago

AbbVie Expands European Reach As Investors Weigh Dividend Support

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. AbbVie received a positive opinion from the European Medicines Agency's CHMP for Boey for glabellar lines and MAVIRET for a... Full story

Yahoo Finance • 7 days ago

The Dividend Stocks That Generate $60,000 Tax-Free Inside a Roth (And What They Cost You in a Taxable Account)

Holding a high-yield dividend portfolio in a taxable account at the 24% federal bracket means writing the IRS a $14,400 check every year on $60,000 of income that should have been yours. It repeats annually, forever, on the same dollars yo... Full story

Yahoo Finance • 7 days ago

AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026

AbbVie Inc. (NYSE:ABBV) is one of the best low risk stocks to buy in 2026. On May 5, AbbVie presented 18 abstracts at the 2026 Digestive Disease Week Annual Meeting, highlighting new real-world and clinical trial data for its IBD therapies... Full story

Yahoo Finance • 8 days ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

The positive opinion is supported by data from the Phase 3 M20-350 study evaluating the safety and efficacy of MAVIRET® in adults with acute hepatitis C virus (HCV) infection. MAVIRET is a direct-acting antiviral (DAA) treatment currently... Full story

Yahoo Finance • 8 days ago

3 Stocks That May Be Trading Below Their Estimated Value In May 2026

The United States market has experienced a flat week but has shown significant growth over the past year with a 27% increase, and earnings are anticipated to grow by 17% annually. In this context, identifying stocks that may be trading bel... Full story

Yahoo Finance • 8 days ago

Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market

Key Points AbbVie's stable business makes it an ideal pick during uncertain times. The stock offers an attractive dividend yield, track record of dividend increases, and valuation. AbbVie's growth prospects help set it apart from other Di... Full story